Li et al. reported the phase 1 trial of NB003, a potent, broad-spectrum TKI that inhibits all KIT and PDGFRA mutations in gastrointestinal stromal tumors (GIST) [52]. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.